Literature DB >> 12576918

Impact of intraoperative radiation on postoperative and disease-specific outcome after pancreatoduodenectomy for adenocarcinoma: a propensity score analysis.

Roderich E Schwarz1, David D Smith, Hemant Keny, David N Iklé, Stephen I Shibata, David Z J Chu, Richard D Pezner.   

Abstract

For periampullary cancer,intraoperative radiation therapy (IORT) administered to the site with the highest locoregional recurrence risk carries the rationale to improve tumor control. An IORT effect on survival remains unclear. IORT impact on postoperative outcomes after pancreatectomy for adenocarcinoma was analyzed, with a specific attempt to correct for the nonrandom IORT treatment assignment, and to account for treatment group imbalances in the interpretation of outcome differences. A propensity-score-adjusted analysis, based on variable selection by logistic regression, was used to rebalance treatments. Between 1989 and 1999, 61 patients underwent partial or total pancreatectomy for a primary periampullary adenocarcinoma at the City of Hope National Medical Center. Diagnoses included pancreatic (n = 36), duodenal (n = 11), ampullary (n = 10), and bile duct cancer (n = 4). Thirty patients received IORT to the resection area, with a median dose of 15 Gy (range: 10-20), followed by postoperative external beam radiation (n = 24). Mortality was 0%, the complication rate 61%. Of 33 patients with a documented recurrence, 6 had an isolated locoregional recurrence only (1 IORT versus 5 no IORT, = 0.05); the systemic recurrence pattern differed as well (IORT 94%, no IORT 67%; = 0.04). IORT had no significant impact on hospital stay (overall median: 17 days), disease-free survival (16 months), and overall survival (23 months) when adjusted for those most relevant variables reflecting IORT treatment group assignment propensity. After adjustment for relevant propensity factors, IORT was not linked to a significantly increased risk for complications, hospital stay, or survival hazard. The recurrence pattern may be affected in some patients, but systemic recurrences predominate. We continue to explore IORT in combination with systemic chemotherapy.

Entities:  

Mesh:

Year:  2003        PMID: 12576918     DOI: 10.1097/00000421-200302000-00004

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  5 in total

1.  Effect of intraoperative radiotherapy combined with external beam radiotherapy following internal drainage for advanced pancreatic carcinoma.

Authors:  Hong-Bing Ma; Zheng-Li Di; Xi-Jing Wang; Hua-Fen Kang; Huai-Ci Deng; Ming-Hua Bai
Journal:  World J Gastroenterol       Date:  2004-06-01       Impact factor: 5.742

Review 2.  A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods.

Authors:  Til Stürmer; Manisha Joshi; Robert J Glynn; Jerry Avorn; Kenneth J Rothman; Sebastian Schneeweiss
Journal:  J Clin Epidemiol       Date:  2005-10-13       Impact factor: 6.437

3.  Efficacy of adjuvant XELOX and FOLFOX6 chemotherapy after D2 dissection for gastric cancer.

Authors:  Ying Wu; Zhe-Wei Wei; Yu-Long He; Roderich E Schwarz; David D Smith; Guang-Kai Xia; Chang-Hua Zhang
Journal:  World J Gastroenterol       Date:  2013-06-07       Impact factor: 5.742

4.  Orthovoltage intraoperative radiation therapy for pancreatic adenocarcinoma.

Authors:  Pavan Bachireddy; Diane Tseng; Melissa Horoschak; Daniel T Chang; Albert C Koong; Daniel S Kapp; Phuoc T Tran
Journal:  Radiat Oncol       Date:  2010-11-08       Impact factor: 3.481

5.  Long-term results of intraoperative electron beam radiation therapy for nonmetastatic locally advanced pancreatic cancer: Retrospective cohort study, 7-year experience with 247 patients at the National Cancer Center in China.

Authors:  Yingtai Chen; Xu Che; Jianwei Zhang; Huang Huang; Dongbing Zhao; Yantao Tian; Yexiong Li; Qinfu Feng; Zhihui Zhang; Qinglong Jiang; Shuisheng Zhang; Xiaolong Tang; Xianghui Huang; Yunmian Chu; Jianghu Zhang; Yuemin Sun; Yawei Zhang; Chengfeng Wang
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.